discussed controversial. In a published randomized controlled trial in hemodialysis patients we could not confirm beneficial effects of cholecalciferol. In parts this ...
Nephrology Dialysis Transplantation 30 (Supplement 3): iii509–iii522, 2015 doi:10.1093/ndt/gfv193.4
CHRONIC KIDNEY DISEASE. NUTRITION, INFLAMMATION AND OXIDATIVE STRESS SP396
CHOLECALCIFEROL SUPPLEMENTATION AND INFLAMMATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
Eric Seibert1, Christof Ulrich2, Bogusz Trojanowicz2, Ulrike Lehmann3, Jutta Dierkes4, Gabriele I Stangl3 and Matthias Girndt2 1 Martin-Luther-University Halle-Wittenberg, Internal Medicine II-Nephrology, Halle (Saale), Germany, 2Martin-Luther-University Halle-Wittenberg, Internal Medicine II Nephrology, Halle (Saale), Germany, 3Martin-Luther-University Halle-Wittenberg, Institute of Agriculture and Nutrition, Halle (Saale), Germany, 4University of Bergen, Department of Clinical Medicine, Bergen, Norway Introduction and Aims: Cholecalciferol supplementation is common clinical practice in chronic kidney diseases. Its effects on mineral metabolism are well documented. However, pleiotropic effects on inflammation independent of active vitamin D are
discussed controversial. In a published randomized controlled trial in hemodialysis patients we could not confirm beneficial effects of cholecalciferol. In parts this may have been due to co-medication with active vitamin D and pre-existing chronic inflammation. In this trial we investigated parameters of cellular inflammation in healthy subjects without pre-existing inflammation or co-medication. Methods: 105 healthy subjects received either 800 I.E./d Cholecalciferol (n=54) or Placebo (n=51) for 12 weeks. Inflammatory monocyte subsets (FACS) and leukocyte expression of inflammatory markers (RT-qPCR) were analysed at baseline and after 12 weeks. Results: In the Cholecalciferol group, 25(OH)D3-levels rose moderately but significantly within 12 weeks (38.1±13.7 vs. 72.5±15.4 nmol/l,p
